drugset / Trial / NCT00681187
Somatuline Autogel Preference and Health Economy Study
RandomizedCrossoverOpen-labelTreatment
Summary
The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanreotide | Other / unclassified | 90 mg | — |
| Subject | Lanreotide | Other / unclassified | 120 mg | — |